Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68106, USA; Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hail, Hail, 81442, Saudi Arabia.
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68106, USA.
Bioorg Med Chem. 2022 Aug 1;67:116805. doi: 10.1016/j.bmc.2022.116805. Epub 2022 May 15.
Angiogenesis inhibitors are a critical pharmacological tool for the treatment of solid tumors. Suppressing vascular permeability leads to inhibition of tumor growth, invasion, and metastatic potential by blocking the supply of oxygen and nutrients. Disruption of the vascular endothelial growth factor (VEGF) signaling pathway is a validated target for the design of antiangiogenic agents. Several VEGFR2 inhibitors have been clinically approved over the past years. Structural analysis of these clinical VEGFR2 inhibitors highlighted key functional group overlap with the benzothiadiazine core contained in a library of in-house compounds. Herein we ascribe anti-angiogenic activity to a series of chlorinated benzothiadiazines. Selected compounds show significant activity to completely ameliorate VEGF-induced endothelial cell proliferation by suppression of VEGFR2 phosphorylation. The scaffold is devoid of activity to inhibit carbonic anhydrases and generally lacks cytotoxicity across a range of cancer and non-malignant cell lines. Assay of activity at 468 kinases shows remarkable selectivity with only four kinases inhibited > 65% at 10 µM concentration, and with significant activity to inhibit TNK2/ACK1 and PKRD2 by > 90%. All four identified kinase targets are known modulators of angiogenesis, thus highlighting compound 17b as a novel angiogenesis inhibitor for further development.
血管生成抑制剂是治疗实体瘤的重要药理学工具。通过阻断氧气和营养物质的供应，抑制血管通透性可导致肿瘤生长、侵袭和转移潜能的抑制。血管内皮生长因子（VEGF）信号通路的破坏是设计抗血管生成药物的有效靶点。过去几年已经有几种 VEGFR2 抑制剂在临床上获得批准。对这些临床 VEGFR2 抑制剂的结构分析突出了与内部化合物库中所含苯并噻二嗪核心的关键功能基团重叠。在此，我们将一系列氯化苯并噻二嗪归因于抗血管生成活性。选定的化合物表现出显著的活性，通过抑制 VEGFR2 磷酸化来完全改善 VEGF 诱导的内皮细胞增殖。该支架对抑制碳酸酐酶没有活性，并且在一系列癌症和非恶性细胞系中通常缺乏细胞毒性。在 468 种激酶中的活性测定显示出显著的选择性，只有 4 种激酶在 10 μM 浓度下被抑制超过 65%，并且对 TNK2/ACK1 和 PKRD2 的抑制活性超过 90%。所有四个鉴定的激酶靶标都是已知的血管生成调节剂，因此突出了化合物 17b 作为进一步开发的新型血管生成抑制剂。
